Agios Pharmaceuticals (AGIO) Current Leases (2019 - 2026)

Agios Pharmaceuticals (AGIO) has 8 years of Current Leases data on file, last reported at $19.2 million in Q2 2026.

• Quarterly Current Leases rose 9.3% year-over-year to $19.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.2 million (up 9.3% YoY) and the FY2025 annual result came in at $18.4 million, up 9.6% from the prior year.
• Current Leases rose to $19.2 million in Q2 2026, from $18.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $19.2 million in Q2 2026 to a low of $11.7 million in Q1 2022.
• A 5-year average of $15.7 million and a median of $15.6 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases surged 47.02% — and 2026, when it increased 9.3%.
• Tracing AGIO's Current Leases over 5 years: stood at $13.7 million in 2022, then grew by 9.84% to $15.0 million in 2023, then gained by 11.81% to $16.8 million in 2024, then rose by 9.6% to $18.4 million in 2025, then gained by 4.53% to $19.2 million in 2026.
• The last three Current Leases figures came in at $19.2 million (Q2 2026), $18.8 million (Q1 2026), and $18.4 million (Q4 2025), per Business Quant data.